Medline annual return on equity
2024
2025
Medline Return on Equity (ROE) Growth & History (MDLN)
Medline's return on equity was 8.50% for fiscal 2025.
View full Medline company overviewMedline annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 · Dec 31 | 2025-12-31 | 8.50% | −5.53 pp |
| 2024 | 2024-12-31 | 14.03% | — |
Medline quarterly return on equity
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-27 | 1.22% | — |
| Q1 2026 | 2026-03-28 | 2.17% | — |
| Q4 2025 | 2025-12-31 | 3.35% | — |
Medline return on equity trends
Between the periods ended 2024-12-31 and 2025-12-31, Medline's return on equity decreased from 14.03% to 8.50%, a change of −5.53 percentage points. The latest reported quarter, Q2 2026, shows 1.22%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Medline source filings ↗